What it's for (Indications)
- Haloperidol is a potent first-generation antipsychotic indicated for the management of various psychiatric and neurological conditions.
- Its primary indications include the treatment of psychotic disorders, such as schizophrenia and acute psychosis, where it effectively reduces positive symptoms like hallucinations and delusions.
- It is also approved for the control of tics and vocalizations in patients with severe Tourette's disorder, providing significant relief from debilitating symptoms.
- Furthermore, haloperidol is utilized in the short-term treatment of severe behavioral problems in children, particularly aggression and hyperactivity that are resistant to other interventions.
- It plays a crucial role in managing acute delirium, often used off-label intravenously in emergency settings, and is indicated for the symptomatic control of chorea associated with Huntington's disease.
- In critical situations, it is also employed for rapid tranquilization or chemical restraint in acutely agitated or violent patients, demonstrating its broad utility across the spectrum of severe mental and neurological health challenges.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of haloperidol is highly individualized and must be carefully titrated based on the patient's age, clinical condition, severity of symptoms, and response to treatment, as well as the specific route of administration. For oral administration in adults with acute psychosis, typical starting doses range from 0.5 mg to 5 mg administered two or three times daily, with a maximum daily dose generally not exceeding 30 mg for severe or resistant cases, though lower doses are preferred. For acute agitation or psychosis requiring rapid control, intramuscular (IM) injections of 2 mg to 5 mg may be given, potentially repeated every 4 to 8 hours depending on response and tolerability, with continuous monitoring for adverse effects. The long-acting decanoate formulation, typically administered intramuscularly every 4 weeks, is used for maintenance treatment of chronic psychotic disorders, with doses usually ranging from 50 mg to 200 mg. Intravenous administration, while common for acute delirium or agitation in critical care settings, is considered off-label and requires stringent cardiac monitoring due to the heightened risk of QTc prolongation. It is imperative that healthcare professionals strictly adhere to prescribing guidelines and conduct regular assessments to optimize therapeutic benefits while minimizing risks, ensuring patient safety through cautious dose escalation and close observation. |
Safety & Warnings
Common Side Effects
- Haloperidol, being a high-potency typical antipsychotic, is associated with a wide range of side effects, primarily stemming from its potent dopamine D2 receptor blockade.
- The most prominent and clinically significant adverse reactions are Extrapyramidal Symptoms (EPS), which include acute dystonia (sustained muscle contractions), akathisia (inner restlessness), parkinsonism (tremor, rigidity, bradykinesia), and potentially irreversible tardive dyskinesia (involuntary, repetitive movements of the face, jaw, or limbs) with prolonged use.
- Other common side effects include sedation or drowsiness, particularly at the initiation of therapy, and anticholinergic effects such as dry mouth, blurred vision, constipation, and urinary retention, although these are generally less pronounced than with low-potency antipsychotics.
- Cardiovascular effects are a serious concern, particularly dose-dependent QT interval prolongation, which can lead to life-threatening ventricular arrhythmias like Torsades de Pointes; orthostatic hypotension is also possible.
- Endocrine disturbances, notably hyperprolactinemia, can manifest as galactorrhea, amenorrhea, gynecomastia, and sexual dysfunction.
- Rare but severe adverse events include Neuroleptic Malignant Syndrome (NMS), characterized by fever, muscle rigidity, altered mental status, and autonomic dysfunction, requiring immediate medical intervention.
- Other potential effects include weight gain, elevated liver enzymes, and a lowered seizure threshold.
- Close monitoring for these adverse effects is crucial throughout treatment.
Serious Warnings
- Black Box Warning: **WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS** Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality in elderly patients with dementia-related psychosis. Haloperidol is not approved for the treatment of dementia-related psychosis.
- Several critical warnings are associated with haloperidol therapy, necessitating careful patient selection and rigorous monitoring.
- A paramount concern is the risk of Neuroleptic Malignant Syndrome (NMS), a rare but potentially fatal idiosyncratic reaction characterized by high fever, severe muscle rigidity, altered mental status, and autonomic instability (e.
- g.
- , irregular pulse or blood pressure, tachycardia, diaphoresis).
- Immediate discontinuation of haloperidol and intensive symptomatic treatment are imperative if NMS is suspected.
- Haloperidol can cause dose-dependent prolongation of the QT interval, increasing the risk of Torsades de Pointes and sudden cardiac death.
- This risk is heightened in patients with pre-existing cardiac conditions, electrolyte imbalances (hypokalemia, hypomagnesemia), or concurrent use of other QT-prolonging drugs.
- Baseline and periodic electrocardiogram (ECG) monitoring, along with electrolyte assessment, is strongly recommended, especially with higher doses or intravenous administration.
- Tardive Dyskinesia (TD), an often irreversible syndrome of involuntary dyskinetic movements, can develop with long-term use; patients should be monitored for its emergence, and consideration given to dose reduction or discontinuation if it occurs.
- Elderly patients with dementia-related psychosis treated with antipsychotics, including haloperidol, are at an increased risk of death, primarily from cardiovascular events or infection; haloperidol is not approved for this indication.
- Orthostatic hypotension, leading to dizziness and falls, can occur, particularly during initial titration.
- The drug can also lower the seizure threshold, warranting caution in patients with a history of epilepsy.
- Anticholinergic effects require careful use in patients with prostatic hypertrophy or narrow-angle glaucoma.
- Additionally, hyperprolactinemia can lead to endocrine disturbances.
- Close vigilance is required for all patients on haloperidol to mitigate these serious risks.
How it Works (Mechanism of Action)
Haloperidol exerts its therapeutic effects primarily through potent antagonism of postsynaptic dopamine D2 receptors in the central nervous system, particularly within the mesolimbic and mesocortical pathways. This blockade is thought to underlie its efficacy in reducing positive symptoms of psychosis, such as hallucinations and delusions, by modulating excessive dopaminergic activity. However, its antagonism of D2 receptors in the nigrostriatal pathway is responsible for the high incidence of extrapyramidal symptoms (EPS), including dystonia, akathisia, and parkinsonism, which are characteristic side effects of high-potency first-generation antipsychotics. Beyond its potent D2 blockade, haloperidol also possesses weaker antagonistic activity at alpha-1 adrenergic receptors, contributing to its potential for orthostatic hypotension. It exhibits some antagonistic effects on muscarinic cholinergic receptors and histamine H1 receptors, although these are generally less pronounced than with lower-potency antipsychotics and contribute to side effects such as mild anticholinergic effects and sedation, respectively. The overall pharmacological profile positions haloperidol as a highly effective agent for acute symptom control, albeit with a significant propensity for motoric side effects due to its non-selective D2 receptor blockade across various brain regions. Its action is rapid and sustained, making it suitable for both acute and maintenance treatment in appropriate patients.